169 related articles for article (PubMed ID: 17652621)
1. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6.
Mottok A; Renné C; Willenbrock K; Hansmann ML; Bräuninger A
Blood; 2007 Nov; 110(9):3387-90. PubMed ID: 17652621
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
[TBL] [Abstract][Full Text] [Related]
3. Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.
Lennerz JK; Hoffmann K; Bubolz AM; Lessel D; Welke C; Rüther N; Viardot A; Möller P
Oncotarget; 2015 Oct; 6(30):29097-110. PubMed ID: 26336985
[TBL] [Abstract][Full Text] [Related]
4. Inactivating SOCS1 mutations are caused by aberrant somatic hypermutation and restricted to a subset of B-cell lymphoma entities.
Mottok A; Renné C; Seifert M; Oppermann E; Bechstein W; Hansmann ML; Küppers R; Bräuninger A
Blood; 2009 Nov; 114(20):4503-6. PubMed ID: 19734449
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT signaling in hematological malignancies.
Vainchenker W; Constantinescu SN
Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
[TBL] [Abstract][Full Text] [Related]
6. Dynamic mathematical modeling of IL13-induced signaling in Hodgkin and primary mediastinal B-cell lymphoma allows prediction of therapeutic targets.
Raia V; Schilling M; Böhm M; Hahn B; Kowarsch A; Raue A; Sticht C; Bohl S; Saile M; Möller P; Gretz N; Timmer J; Theis F; Lehmann WD; Lichter P; Klingmüller U
Cancer Res; 2011 Feb; 71(3):693-704. PubMed ID: 21127196
[TBL] [Abstract][Full Text] [Related]
7. JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
Steensma DP; McClure RF; Karp JE; Tefferi A; Lasho TL; Powell HL; DeWald GW; Kaufmann SH
Leukemia; 2006 Jun; 20(6):971-8. PubMed ID: 16598306
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.
Weniger MA; Melzner I; Menz CK; Wegener S; Bucur AJ; Dorsch K; Mattfeldt T; Barth TF; Möller P
Oncogene; 2006 Apr; 25(18):2679-84. PubMed ID: 16532038
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders.
Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M
Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760
[TBL] [Abstract][Full Text] [Related]
10. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
11. Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma.
Tiacci E; Ladewig E; Schiavoni G; Penson A; Fortini E; Pettirossi V; Wang Y; Rosseto A; Venanzi A; Vlasevska S; Pacini R; Piattoni S; Tabarrini A; Pucciarini A; Bigerna B; Santi A; Gianni AM; Viviani S; Cabras A; Ascani S; Crescenzi B; Mecucci C; Pasqualucci L; Rabadan R; Falini B
Blood; 2018 May; 131(22):2454-2465. PubMed ID: 29650799
[TBL] [Abstract][Full Text] [Related]
12.
Schuhmacher B; Bein J; Rausch T; Benes V; Tousseyn T; Vornanen M; Ponzoni M; Thurner L; Gascoyne R; Steidl C; Küppers R; Hansmann ML; Hartmann S
Haematologica; 2019 Feb; 104(2):330-337. PubMed ID: 30213827
[TBL] [Abstract][Full Text] [Related]
13. Methylation of the suppressor of Cytokine Signaling 1 Gene (SOCS1) in Philadelphia-negative myeloproliferative neoplasms.
Yasin EB; Alserihi R; Alkhatabi H; Qutob HMH; Qahwaji R; Kattan SW; Gholam KA; Hussein E; Barefah AS; Alghuthami ME; Abuzenadah A
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(22):8451-8458. PubMed ID: 36459028
[TBL] [Abstract][Full Text] [Related]
14. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development.
Roncero AM; López-Nieva P; Cobos-Fernández MA; Villa-Morales M; González-Sánchez L; López-Lorenzo JL; Llamas P; Ayuso C; Rodríguez-Pinilla SM; Arriba MC; Piris MA; Fernández-Navarro P; Fernández AF; Fraga MF; Santos J; Fernández-Piqueras J
Leukemia; 2016 Jan; 30(1):94-103. PubMed ID: 26216197
[TBL] [Abstract][Full Text] [Related]
15. [Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in MedB-1 mediastinal lymphoma line].
Barth TF; Melzner I; Wegener S; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Leithäuser F; Möller P
Verh Dtsch Ges Pathol; 2005; 89():234-44. PubMed ID: 18035697
[TBL] [Abstract][Full Text] [Related]
16. Both the suppressor of cytokine signaling 1 (SOCS-1) kinase inhibitory region and SOCS-1 mimetic bind to JAK2 autophosphorylation site: implications for the development of a SOCS-1 antagonist.
Waiboci LW; Ahmed CM; Mujtaba MG; Flowers LO; Martin JP; Haider MI; Johnson HM
J Immunol; 2007 Apr; 178(8):5058-68. PubMed ID: 17404288
[TBL] [Abstract][Full Text] [Related]
17. Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Ritz O; Guiter C; Castellano F; Dorsch K; Melzner J; Jais JP; Dubois G; Gaulard P; Möller P; Leroy K
Blood; 2009 Aug; 114(6):1236-42. PubMed ID: 19423726
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Jost E; do O N; Dahl E; Maintz CE; Jousten P; Habets L; Wilop S; Herman JG; Osieka R; Galm O
Leukemia; 2007 Mar; 21(3):505-10. PubMed ID: 17230231
[TBL] [Abstract][Full Text] [Related]
19. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells.
Baus D; Pfitzner E
Int J Cancer; 2006 Mar; 118(6):1404-13. PubMed ID: 16206268
[TBL] [Abstract][Full Text] [Related]
20. Alterations of negative regulators of cytokine signalling in immunodeficiency-related non-Hodgkin lymphoma.
Capello D; Gloghini A; Baldanzi G; Martini M; Deambrogi C; Lucioni M; Piranda D; Famà R; Graziani A; Spina M; Tirelli U; Paulli M; Larocca LM; Gaidano G; Carbone A; Sinigaglia F
Hematol Oncol; 2013 Mar; 31(1):22-8. PubMed ID: 22488585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
